Brousset P, Drouet E, Schlaifer D, Icart J, Payen C, Meggetto F, Marchou B, Massip P, Delsol G
Department of Pathology, Centre Hospitalier Universitaire de Purpan, Toulouse, France.
AIDS. 1994 May;8(5):583-90. doi: 10.1097/00002030-199405000-00003.
To determine whether activation of Epstein-Barr virus (EBV) replication in tumour cells of AIDS-related non-Hodgkin's lymphoma (ARNHL) is correlated with CD4+ cell counts and influences antibody response to EBV [anti-Z Epstein-Barr replicative activator (ZEBRA), anti-early antigen (EA), anti-viral capsid antigen (VCA)].
Retrospective study based on immunohistochemistry and in situ hybridization to detect EBV replicative gene products in tissue samples from patients affected by ARNHL and correlation with CD4+ cell counts and results of EBV serology (including anti-ZEBRA activity) in sera from the same patients.
Seventeen out of 22 cases of ARNHL were selected for the presence of EBV [Epstein-Barr early region (EBER) RNA-positive]. Immunohistochemistry was performed with anti-ZEBRA, anti-EA-restricted, anti-VCA antibodies and in situ hybridization with BHLF1/NotI oligoprobes on tumour samples. Results were statistically correlated with those of CD4+ cell counts (17 out of 17) and with anti-EBV antibody titres (13 out of 17) assessed using standard immunofluorescence method and enzyme-linked immunosorbent assay procedure using recombinant ZEBRA protein and synthetic peptides as antigens.
BZLF1 (ZEBRA) or early gene products (EA-R and EA-D/BHLF1/NotI) were detected in a small proportion (< 0.01-5%) of tumour cells in eight of these 17 cases by immunohistochemistry and in situ hybridization. Demonstration of replicative gene expression did not correlate with either low CD4+ cell counts (P > 0.05) or anti-EBV antibody titres (P > 0.05). Anti-ZEBRA activity was not significantly increased in patients affected with ARNHL, the cells of which expressed replicative gene products (P > 0.05).
The degree of immunodeficiency does not clearly enhance replicative gene expression in tumour cells of ARNHL. EBV serology, including anti-ZEBRA activity, is not a reliable tool for predicting the occurrence of such proliferations.
确定艾滋病相关非霍奇金淋巴瘤（ARNHL）肿瘤细胞中爱泼斯坦-巴尔病毒（EBV）复制的激活是否与CD4+细胞计数相关，并影响对EBV的抗体反应[抗Z爱泼斯坦-巴尔病毒复制激活剂（ZEBRA）、抗早期抗原（EA）、抗病毒衣壳抗原（VCA）]。
基于免疫组织化学和原位杂交的回顾性研究，以检测ARNHL患者组织样本中的EBV复制基因产物，并与同一患者的CD4+细胞计数及EBV血清学结果（包括抗ZEBRA活性）相关联。
在22例ARNHL病例中，选取17例存在EBV[爱泼斯坦-巴尔早期区域（EBER）RNA阳性]的病例。对肿瘤样本进行抗ZEBRA、抗EA特异性、抗VCA抗体的免疫组织化学检测，以及与BHLF1/NotI寡核苷酸探针的原位杂交。结果与CD4+细胞计数结果（17例中的17例）以及使用标准免疫荧光法和以重组ZEBRA蛋白和合成肽为抗原的酶联免疫吸附测定程序评估的抗EBV抗体滴度（17例中的13例）进行统计学关联。
通过免疫组织化学和原位杂交，在这17例中的8例肿瘤细胞中检测到小比例（<0.01-5%）的BZLF1（ZEBRA）或早期基因产物（EA-R和EA-D/BHLF1/NotI）。复制基因表达的证实与低CD4+细胞计数（P>0.05）或抗EBV抗体滴度（P>0.05）均无相关性。在ARNHL患者中，其细胞表达复制基因产物的患者，抗ZEBRA活性未显著增加（P>0.05）。
免疫缺陷程度并未明显增强ARNHL肿瘤细胞中的复制基因表达。包括抗ZEBRA活性在内的EBV血清学不是预测此类增殖发生的可靠工具。
